Joo Hang Kim

7.2k total citations · 1 hit paper
91 papers, 3.0k citations indexed

About

Joo Hang Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Joo Hang Kim has authored 91 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Joo Hang Kim's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (29 papers) and Neuroendocrine Tumor Research Advances (12 papers). Joo Hang Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (29 papers) and Neuroendocrine Tumor Research Advances (12 papers). Joo Hang Kim collaborates with scholars based in South Korea, United States and Singapore. Joo Hang Kim's co-authors include Byoung Chul Cho, Sun Young Rha, Hye Ryun Kim, Kurt Krejcy, Yi‐Long Wu, Maciej Krzakowski, Jayaprakash Madhavan, Stephen Begbie, Isabel Bover and Sung Hyun Yang and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Joo Hang Kim

90 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

2009 832 citations Joo Hang Kim et al. profile →

Peers

Countries citing papers authored by Joo Hang Kim

Since Specialization

Citations

This map shows the geographic impact of Joo Hang Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joo Hang Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joo Hang Kim more than expected).

Fields of papers citing papers by Joo Hang Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joo Hang Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joo Hang Kim. The network helps show where Joo Hang Kim may publish in the future.

Co-authorship network of co-authors of Joo Hang Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Joo Hang Kim. A scholar is included among the top collaborators of Joo Hang Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joo Hang Kim. Joo Hang Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial 2025 ·Cancer Research and Treatment ·(unknown), (unknown), Min Kyoung Kim, Keon Uk Park, Tak Yun, Keun‐Wook Lee, Joo Hang Kim, Bhumsuk Keam, Byoung Chul Cho, So Yeon Oh, Sang‐Hee Cho, Sangwoo Kim, Sung‐Bae Kim, Min Hee Hong, Hye Ryun Kim	1
2	STING signaling is a potential immunotherapeutic target in colorectal cancer 2019 ·Journal of Cancer ·Hong Jae Chon, Hyojoong Kim, Jung Hyun Noh, Hannah Yang, Won Suk Lee, So Jung Kong, Seung‐Jun Lee, (unknown), Woo Ram Kim, Joo Hang Kim, Gwangil Kim, Chan Kim	64
3	Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study 2016 ·Journal of Thoracic Oncology ·Myung‐Ju Ahn, Sung Hee Lim, Jong‐Mu Sun, Yoon‐La Choi, Hye Ryun Kim, Soomin Ahn, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Joo Hang Kim, Byoung Chul Cho	5
4	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET -Rearranged Lung Adenocarcinoma 2015 ·Molecular Cancer Therapeutics ·Chan Woo Kang, (unknown), Jinyoung Sohn, Sung‐Moo Kim, Kyoung‐Ho Pyo, Il Hwan Kim, Mi Ran Yun, Han Na Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, Dae Joon Kim, Joo Hang Kim, Byoung Chul Cho	16
5	The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer 2015 ·Lung Cancer ·Ji Soo Park, (unknown), Eun Young Kim, Ji Ye Jung, Soon Il Kim, Joon Chang, Dae Joon Kim, Chang Young Lee, Inkyung Jung, Joo Hang Kim, Hye Ryun Kim, Yong Wha Moon, Hyo Song Kim, Byoung Chul Cho, Hyo Sup Shim	7
6	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma 2014 ·Lung Cancer ·Hye Ryun Kim, Byoung Chul Cho, Hyo Sup Shim, Sun Min Lim, Soon Il Kim, Joon Chang, Dae Joon Kim, Joo Hang Kim	35
7	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors 2013 ·Supportive Care in Cancer ·Han Sang Kim, Sang Joon Shin, Sang Cheol Kim, (unknown), Sun Young Rha, Joong Bae Ahn, Byoung Chul Cho, Hye Jin Choi, Joohyuk Sohn, Hyo Song Kim, Hyun Cheol Chung, Joo Hang Kim, Jae Kyung Roh, Soo Hyun Lee	38
8	Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation 2012 ·Molecular Cancer Therapeutics ·Sun Mi Kim, Oh-Joon Kwon, Yun Hong, Joo Hang Kim, Flavio Solca, Sang‐Jun Ha, Ross A. Soo, James G. Christensen, Ji Hyun Lee, Byoung Chul Cho	172
9	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib 2011 ·Experimental and Therapeutic Medicine ·Minkyu Jung, Se Hyun Kim, Young Joo Lee, Soojung Hong, Young Ae Kang, Se Kyu Kim, Joon Chang, Sun Young Rha, Joo Hang Kim, Dae Joon Kim, Byoung Chul Cho	28
10	A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results 2010 ·Lung Cancer ·Hye Jin Choi, Joohyuk Sohn, Chang Geol Lee, Hyo Sup Shim, Ik Jae Lee, Woo Ick Yang, Ji Eun Kwon, Soon Il Kim, Moo Suk Park, Ju Hee Lee, Joo Hang Kim	33
11	Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients 2010 ·Oncology ·Soojung Hong, Byoung Chul Cho, Hye Jin Choi, Minkyu Jung, Soo Hyun Lee, Kyong Soo Park, Se Kyu Kim, Joo Hang Kim	14
12	Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck 2009 ·Cancer Chemotherapy and Pharmacology ·Byoung Chul Cho, Ki Chang Keum, Sang Joon Shin, Hye Jin Choi, Young Joo Lee, Se Hoon Kim, Eun Chang Choi, Joo Hang Kim	23
13	Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients 2008 ·BMC Cancer ·Byoung Chul Cho, Joong Bae Ahn, Jinsil Seong, Jae Kyung Roh, Joo Hang Kim, Hyun Cheol Chung, Joohyuk Sohn, Nam Kyu Kim	17
14	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy 2007 ·Cancer Chemotherapy and Pharmacology ·Hye Jin Choi, Byoung Chul Cho, Sang Joon Shin, Seong Ha Cheon, (unknown), Joon Chang, Soon Il Kim, Joohyuk Sohn, Joo Hang Kim	12
15	Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Su Jung Shim, Woo-Ick Yang, Eunah Shin, Woong Sub Koom, Yong Bae Kim, Jaeho Cho, Chang‐Ok Suh, Joo Hang Kim, Gwi Eon Kim	20
16	Clinical Features of Bronchogenic Large Cell Carcinoma Confirmed by Surgical Resection 2003 ·The Korean Journal of Internal Medicine ·Moo Suk Park, Dong Hwan Shin, Kyung Soo Chung, (unknown), (unknown), Do Hoon Kim, Se Kyu Kim, Joon Chang, Joo Hang Kim, Sung Kyu Kim, Young Sam Kim	4
17	Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer 2002 ·Cancer Research and Treatment ·Chul Kim, Joohyuk Sohn, Joo Hang Kim, Soon Il Kim, Young Sam Kim, Joon Chang, Y. Choi	2
18	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients 1998 ·Breast Cancer Research and Treatment ·Hyun Cheol Chung, Sun Young Rha, Joon Oh Park, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung‐Soo Kim, Jin Ju Kim	15
19	A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy 1997 ·American Journal of Clinical Oncology ·Joon Oh Park, Sun Young Rha, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Byung‐Soo Kim, Hyun Cheol Chung	11
20	Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer 1997 ·American Journal of Clinical Oncology ·Joon Oh Park, Hyun Cheol Chung, Y. Choi, Sun Young Rha, (unknown), Joo Hang Kim, Sung Hoon Noh, Choong Bai Kim, Jin Sik Min, Byung‐Soo Kim, Jae Kyung Roh	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact